Tizanidine Tablet
Product Images NDC 50268-760

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 50268-760). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2 (2mg)

This is a description of Tizanidine tablets, which are prescription medication with the active ingredient of Tizanidine hydrochloride USP, which is equivalent to 2 mg of Tizanidine base. These tablets are not interchangeable with Tizanidine capsules. The tablets are available in a pack of 50 tablets or 5X10 unit dose. The package insert should be referred to for prescribing information. The tablets should be stored at a controlled room temperature between 15°-30°C (59°-86°F) and kept out of reach of children. These tablets are manufactured by Avkare in Pulaski, TN.*

FDA Label Image

4 (4mg.)

This is a product description for Tizanidine Tablets USP, containing 50 tablets (5 x 10) unit dose, manufactured exclusively for Avkare Inc. The tablets contain 4.576mg tizanidine HCl USP, equivalent to 4mg tizanidine base and should be stored between 15°-30°C. The product comes with a package insert for prescribing information and is only available through a prescription. Tizanidine Tablets cannot be substituted with Tizanidine Capsules.*

FDA Label Image

Fig1 (Fig1)

This text shows a chart displaying plasma Tzanidine concentration or levels (in ng/mL) at different hours from dosing. The chart compares the levels of 4 mg Tzanidine tablets and capsules taken with or without food. The text also includes labels for each data point indicating which dosing method (tablets or capsules with or without food) was used. There is a reference to the source of the data, but it is not readable due to errors.*

FDA Label Image

Fig2 (Fig2)

FDA Label Image

Fig3 (Fig3)

This is a study evaluating the improvement in Ashworth Score after treatment with zanidine. The mean dose used in the study was 28.6 mg. The study lasted seven weeks, and the improvement was evaluated at week 3 and the end of maintenance endpoint, which was the last observation carried forward.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.